📋 Tender Overview
Scope : To Construct a new $2.5 billion High-Tech Pharmaceutical Manufacturing Site in Alzey, Rhineland-Palatinate, Germany.
Eli Lilly and Co. (LLY) announced plans to construct a new $2.5 billion high-tech manufacturing site in Alzey, Rhineland-Palatinate, Germany. This will further expand the company's global parenteral (injectable) product and device manufacturing network.
With extensive experience across the pharmaceutical industry, Germany's workforce will play a vital role in bolstering Lilly's incretin supply when the new site is operational beginning in 2027. The site in Alzey will employ up to 1,000 highly skilled workers such as engineers, operators and scientists.
In addition, an estimated 1,900 jobs will be created during construction, which is scheduled to begin in 2024. Lilly's investment in Alzey is contingent upon finalization of government permitting and local approvals.
